In patients with vasodilatory shock on high-dose vasopressors, intravenous administration of angiotensin II increased blood pressure and consequently allowed catecholamine dose reduction when compared to placebo at 3 hours of therapy. Level of evidence: 1B (Randomised controlled trial with a low risk of bias)